What is CLRB's current stock price?

CLRB (Cellectar Biosciences, Inc.) is currently trading at $3.20 with a market cap of $10.2M.

What sector is Cellectar Biosciences, Inc. in?

Cellectar Biosciences, Inc. (CLRB) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is CLRB a good stock to buy?

Analysts have a Buy consensus on CLRB with a price target of $11.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

CLRB Cellectar Biosciences, Inc.

Healthcare

$3.20+0.95%ClosedMarket Cap: $10.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.88

P/S

0.00

EV/EBITDA

-0.15

DCF Value

$4.38

FCF Yield

-182.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-264.8%

ROA

-187.4%

ROIC

-358.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-5.7M	$—
Q4 null	$0.00	$-5.3M	$—
FY null	$0.00	$-21.8M	$—
Q3 null	$0.00	$-4.4M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$11.00

Target (Median)

$11.00

Target Range

$11.00 - $11.00

1 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell

Maxim GroupBuy

2026-03-10

Trading Activity

Insider Trades

View All

Longcor Jarrodofficer: Chief Operating Officer

BuyMon May 11

Longcor Jarrodofficer: Chief Operating Officer

BuyMon May 11

CARUSO JAMES Vdirector, officer: Chief Executive Officer

BuyMon May 11

CARUSO JAMES Vdirector, officer: Chief Executive Officer

BuyMon May 11

NEIS JOHNdirector

SellTue Dec 16

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.43

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Peers